Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;113(4):349-64; quiz 465-6.
doi: 10.1007/s00347-016-0239-3.

[Graves' ophthalmopathy]

[Article in German]
Affiliations
Review

[Graves' ophthalmopathy]

[Article in German]
A Eckstein et al. Ophthalmologe. 2016 Apr.

Abstract

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease and the full clinical picture can impair the quality of life of the patients considerably. Active inflammation can often be effectively treated by intravenous steroids/immunosuppression, however does not lead to full remission, since inflammation rather quickly results in irreversible fibrosis and increase of orbital fat. Very important is the control of risk factors (smoking cessation, good control of thyroid function, selenium supplementation) to prevent progression to severe stages. Treatment should rely on a thorough assessment of activity and severity of GO. Rehabilitative surgery (orbital decompression, squint surgery, eyelid surgery) is needed in many patients to restore function and appearance. Anti-thyroid-stimulating hormone (TSH) receptor antibodies do specifically occur in these patients and correlate to the course of thyroid and eye disease. The levels of these antibodies can be used for treatment decisions at certain time points of the disease.

Keywords: Graves’ disease; Graves’ orbitopathy; Immunmodulatory therapy; Reconstructive surgical procedures; Thyroid-stimulating hormone receptor.

PubMed Disclaimer

References

    1. J Endocrinol Invest. 2004 Mar;27(3):265-71 - PubMed
    1. Clin Endocrinol (Oxf). 2005 Feb;62(2):145-55 - PubMed
    1. Am J Ophthalmol. 1993 Nov 15;116(5):533-47 - PubMed
    1. J Clin Endocrinol Metab. 2009 Aug;94(8):2708-16 - PubMed
    1. Ophthalmologe. 2007 Sep;104(9):771-6 - PubMed

MeSH terms

Substances

LinkOut - more resources